What is the recommendation for using a GP IIb/IIIa inhibitor in patients with NSTE-ACS and high-risk features?
It is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban) at the time of PCI for patients with NSTE-ACS and high-risk features (eg, elevated troponin) treated with UFH and adequately pretreated with clopidogrel. (Level of Evidence: B)